Navigation Links
Study suggests blood test can help improve treatment outcomes for breast cancer patients
Date:5/15/2008

Washington, DC -- With the goal of tailoring cancer treatment for each individual, researchers at Georgetown University Medical Center today presented a study suggesting a simple blood test can help doctors more reliably assess treatment efficacy for patients with metastatic breast cancer.

It can take several weeks and sometimes months to determine if a particular cancer treatment is working because it can take that long to observe any significant radiographic changes in tumor size or appearance, says Minetta Liu, M.D., of Georgetowns Lombardi Comprehensive Cancer Center. Right now, we have to rely on radiology studies such as CT scans, ultrasound, and the like to determine whether or not there is disease progression. With this new blood test, we have another reliable tool that may allow us to determine much sooner if a therapy is ineffective so that we can change therapy earlier and potentially make more significant improvements in survival.

Using the FDA-approved CellSearch technology, researchers measured the number of circulating tumor cells (CTC) in blood collected from women with metastatic breast cancer. About one tablespoon of blood was collected every three to four weeks. The number of CTCs was correlated with disease response or progression as determined by standard radiology studies performed every 9-12 weeks. The women in the study received various treatments including chemotherapy, endocrine therapy, and combination therapy with a biologic agent.

A CTC count of five was used as the threshold, based on previous studies. There was a highly significant difference in the distribution of progression between two groups of patients defined by their CTC result. Seventy-one percent of patients who had a CTC greater than or equal to five had disease progression, and 66 percent of patients with a CTC count of less than five did not.

A CTC count of five or greater at the time of restaging was associated with a 5.32 fold increase in a patients chance of having disease progression compared to CTC counts of less than five, explains Liu. CTC assessments should be used as a surrogate marker for treatment efficacy and disease responsiveness. Changes in CTC results from less than five to greater than or equal to five over time may herald disease progression.

Liu adds that the CTC assay is a more reliable means of assessing treatment response than the traditional tumor markers currently in use.

We have a follow-up study underway that evaluates CTC results within the framework of a randomized clinical trial to eliminate potential variability from the treatment administered, says Liu, the national principal investigator of the new trial. Liu and her colleagues believe a study with the same therapies would offer even stronger evidence for routine use of CTC in patients with metastatic breast cancer.

We have many treatment options for advanced breast cancer. The key is to find the most effective therapy for each patient. It shouldnt take months to figure that out, she concludes.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Study takes a step toward better defining fatigue
2. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
3. Study finds parents use cough medicines on under-2s despite the warnings
4. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
5. Study Supports Popular HIV Drug Regimen
6. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
7. Study shows that prostate cancer increases the risk of bone fracture
8. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
9. Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds
10. New Study: Texas Seniors 4th Hardest-Hit from Proposed Bush Administration Medicare Cuts
11. Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: